HCG Q1 FY27: Consolidated revenue rises 13%, PAT up 175% YoY to Rs 16.5 cr

Profit growth above 25%Exceptional itemRelated-party transactionsResults View source PDF Explain this filing

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹674.00

prior close

₹670.10

announcement price

After-mkt

timing

Nifty Microcap 250market+0.0%+0.6% vs market

Hospital peers, median of 26sector+0.2%+0.4% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.4 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

-1.0

15m

-1.5

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+0.0+0.6+0.2+0.4

Next day

+6.2-0.0+6.2-0.1+6.3

+8.1-0.2+8.3-0.4+8.6

+9.3+0.2+9.2-2.1+11.5

+7.1+0.3+6.8-3.0+10.1

+6.0+0.4+5.6-1.7+7.7

+5.8+0.9+4.9-1.6+7.3

15d

+3.1+1.6+1.5-3.1+6.1

+2.3+2.0+0.3-2.5+4.8

-2.4+0.6-2.9-10.4+8.1

—————

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

HCG posted strong Q1 FY27 results. Consolidated revenue rose 13% YoY to Rs 693 crore from Rs 612 crore. Profit after tax jumped 175% to Rs 16.5 crore versus Rs 6 crore. Standalone revenue grew 15% to Rs 375 crore; PAT was Rs 5.6 crore versus Rs 3.5 crore. Board approved Rs 16 crore further investment in wholly owned subsidiary HCG Rajkot Hospitals LLP and re-appointed Cost Auditor. Recently completed BACC Healthcare divestment for Rs 37.6 crore to a related party. Rights issue proceeds now fully utilised. Auditor gave unqualified limited review report.

Likely market impact

Strong Q1 with sharp PAT growth signals improving margins and an operational turnaround; investor focus on subsidiary investments.